Ascertainment of testosterone prescribing practices in the VA

Medical Care

Volumn 53, Issue 9, 2015, Pages 746-752

  Jasuja, Guneet K ^a,b   Bhasin, Shalender ^c   Reisman, Joel I ^a   Berlowitz, Dan R ^a,b   Rose, Adam J ^a,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Guidelines; Testosterone prescribing; VA

Indexed keywords

FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ARTICLE; BREAST CANCER; CROSS-SECTIONAL STUDY; ELECTRONIC MEDICAL RECORD; FOLLITROPIN BLOOD LEVEL; HUMAN; HYPOGONADISM; INTEGRATED HEALTH CARE SYSTEM; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY ANALYSIS; SLEEP DISORDERED BREATHING; VETERAN; CLINICAL PRACTICE; DEFICIENCY; GOVERNMENT; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; TESTOSTERONE; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84942592013     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000398     Document Type: Article

References (30)

1. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
2. Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173:1465-1466.
3. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-731.
4. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87:589-598.
5. Spitzer M, Huang G, Basaria S, et al. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol. 2013;9:414-424.
6. Xu L, Freeman G, Cowling BJ, et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.
7. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34:828-837.
8. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
9. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829-1836.
10. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of nonfatal myocardial infarction following testosterone therapy dispensing in men. PLoS One. 2014;9:e85805.
11. Tavernise S. FDA Panel Backs Limits on Testosterone Drugs. New York: The New York Times Company. Available at: www.nytimes/com/2014/09/18/health/testosterone-drugs-fda.html. Accessed September 17, 2014.
12. Drehle DV. Manopause?! Aging, Insecurity and the $2 Billion Testosterone Industry. New York: Time Inc; 2014. Available at: http://time.com/3062889/manopause-aging-insecurity-and-the-2-billion-testosteroneindustry/#3062889/manopause-aging-insecurity-and-the-2-billiontestosteroneindustry/. Accessed December 9, 2014.
13. US Food and Drug Administration. FDA Drug Safety Communication: FDA Evaluating Risk of Stroke, Heart Attack and Death with FDAapproved Testosterone Products. Maryland: US Department of Health and Human Services; 2014. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm. Accessed January 31, 2014.
14. US Food and Drug Administration. FDA Adding General Warning to Testosterone Products About Potential for Venous Blood Clots. Maryland: US Department of Health and Human Services; 2014. Available at: http://www.fda.gov/drugs/drugsafety/ucm401746.htm. Accessed June 19, 2014.
15. Dobs AS. Androgen therapy in AIDS wasting. Baillieres Clin Endocrinol Metab. 1998;12:379-390.
16. Grinspoon S, Corcoran C, Parlman K, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med. 2000;133:348-355.
17. Petak SM, Nankin HR, Spark RF, et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract. 2002;8:440-456.
18. Wang C, Nieschlag E, Swerdloff R, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of lateonset hypogonadism in males. Int J Impot Res. 2009;21:1-8.
19. Bhasin S, Pencina MJ, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham heart study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96:2430-2439.
20. Hynes DM, Koelling K, Stroupe K, et al. Veterans' access to and use of Medicare and Veterans Affairs health care. Med Care. 2007;45:214-223.
21. Yu W, Ravelo A, Wagner TH, et al. Prevalence and costs of chronic conditions in the VA health care system. Med Care Res Rev. 2003;60(suppl):146S-167S.
22. Layton JB, Li D, Meier CR, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000-2011. J Clin Endocrinol Metab. 2014;99:835-842.
23. Baillargeon J, Urban RJ, Kuo YF, et al. Screening and monitoring in men prescribed testosterone therapy in the US, 2001-2010. Public Health Rep. 2015;130:143-152.
24. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458-1465.
25. Gentry J, Price DJ, Peiris AN. Hypogonadism in primary care: the lowdown on low testosterone. South Med J. 2013;106:492.
26. Jamtvedt G, Young JM, Kristoffersen DT, et al. Audit and feedback: effects on professional practice and health care outcomes (review). Cochrane Database Syst Rev. 2006;2:CD00259.
27. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. Milbank Q. 1996;74:511-544.
28. Sim I, Gorman P, Greenes RA, et al. Clinical decision support systems for the practice of evidence-based medicine. J AmMed Inform Assoc. 2001;8:527-534.
29. Ferver K, Burton B, Jesilow P. The use of claims data in healthcare research. Open Public Health J. 2009;2:11-24.
30. Jha AK, Perlin JB, Kizer KW, et al. Effect of the transformation of the Veterans Affairs Health Care System on the quality of care. N Engl J Med. 2003;348:2218-2227.